Real-World Study Finds LEQEMBI Stabilizes Early Alzheimer’s Patients

More than 82% of patients with early-stage Alzheimer’s disease remained stable or showed improvement after an average of 17 months on LEQEMBI therapy, according to new real-world data presented at the 2026 Alzheimer’s Association International Conference in London.

Money Talk·July 14, 2026·reads: 972

The LEADER study, a retrospective analysis involving 432 participants across 13 U.S. clinical sites, tracked the effectiveness of the drug in real-world settings outside of traditional controlled trials. Researchers found that 75.9% of patients maintained their disease stage, while 6.6% showed clinical improvement by transitioning from mild Alzheimer’s dementia to mild cognitive impairment. These outcomes remained consistent regardless of the patients' sex, race, ethnicity, or APOE genotype.

Nearly 87% of those enrolled chose to persist with the treatment, with many transitioning to maintenance dosing regimens. Safety findings were largely aligned with the drug's FDA-approved label. Amyloid-related imaging abnormalities (ARIA) were observed in 12.3% of the study population, though most cases were classified as asymptomatic or mild in severity. The study underscores the potential for continuous treatment to help manage the progression of early Alzheimer’s disease in diverse clinical environments.